Thermo Fisher Scientific (TMO) Debt to Equity (2009 - 2026)

Thermo Fisher Scientific has disclosed Debt to Equity across 18 years of filings, most recently posting $0.83 for Q1 2026.

• Quarterly Debt to Equity rose 19.98% year-over-year to $0.83 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.83 (up 19.98% YoY) and the FY2025 annual result came in at $0.74, up 16.82% from the prior year.
• Debt to Equity grew to $0.83 in Q1 2026, from $0.74 in the prior quarter.
• Over five years, Debt to Equity peaked at $0.83 in Q2 2023 and troughed at $0.63 in Q4 2024.
• A 5-year average of $0.74 and a median of $0.75 in 2024 frame the typical range for Debt to Equity.
• Annual changes were most pronounced in 2022 — Debt to Equity surged 52.49% — and 2024, when it declined 15.54%.
• Tracing TMO's Debt to Equity over 5 years: stood at $0.78 in 2022, then dropped by 4.59% to $0.75 in 2023, then dropped by 15.54% to $0.63 in 2024, then advanced by 16.82% to $0.74 in 2025, then gained by 12.71% to $0.83 in 2026.
• Business Quant data shows TMO's Debt to Equity at $0.83 in Q1 2026, $0.74 in Q4 2025, and $0.7 in Q3 2025.